Page 242 - Drug Class Review
P. 242
Page 151 of 205
Drug Effectiveness Review Project
To investigate whether GAL significantly improves the core symptoms of AD
placebo N/A 3 months 87 Male and female outpatients with mild to moderate AD as defined by NINCDS/ADRDA and MMSE (score 13-24) aged >45 years who were attending memory clinics; required to have appropriate caregiver Dementia secondary to causes other than AD or any condition considered likely to interfere with the trial Antidepressants; antipsychotic drugs; antiparkinsonian drugs; insulin; anticonvulsants; sedatives; antihypertensive agents (except ACE inhibitors and diuretics); other cholinergic or anticholinergic agents
Drugs Authors: Wilkinson et al. 54 Shire Phamaceuticals Setting: Multi-center galantamine 18; 24; 36 mg/d 3 months 88; 56; 54 in the opinion of the investigator (except inhaled drugs for asthma)
Alzheimer Year: 2001 Country: UK Study design: RCT Sample size: 285
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
